Hear What Our Partners Have to Say About the CardioCare Platform
The Solution 
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.
The Solution
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.
Customer Spotlight
Nicole Festa, PA-C shares insights from St. Luke's University Health Network
Katie Worthington, NP shares insights from Morristown Medical Center
Using AI to Identify and Improve Outcomes for Cardiovascular Patients
with Dr. Ben Peterson
AI-Powered Breakthroughs in Cardiovascular Access with The Christ Hospital Health Network
Partner Sites
Working with Top Cardiovascular Programs Across the U.S.
Don't just take our word for it. Talk to our team today to learn more about partnerships.
MORE CONTENT
Subscribe to Our YouTube Channel
Testimonials
Leading hospitals partner with egnite’s CardioCare platform to reduce variability in care and improve guideline-directed therapy for patients with cardiovascular disease.
Gagnon Cardiovascular Institute, Morristown Medical Center
Resources
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
ALISO VIEJO, Calif. – July 1, 2025 – egnite, Inc., a leading digital health company advancing cardiovascular innovation, today announced the launch of its new CardioCare Research Suite, a significant expansion of its flagship platform that enables hospitals to automatically identify patients eligible for clinical trials across participating health systems.